Altamira Therapeutics Company Overview
About Altamira Therapeutics
Altamira Therapeutics (NASDAQ:CYTO) is a biopharmaceutical company focused on developing novel treatments for diseases related to hearing and balance disorders, as well as therapeutics in the field of RNA (Ribonucleic Acid) interference. The company is dedicated to advancing its pipeline through rigorous scientific research to meet unmet medical needs across various patient populations. Their projects range from early-stage research in gene therapy for hearing loss to developing innovative RNA-based therapeutics targeting specific diseases. Altamira's objective is to improve patients' lives by delivering groundbreaking therapies that address some of the most challenging conditions related to ear health. The company is traded on the NASDAQ stock exchange under the ticker code CYTO, showcasing a commitment to transparency and investor relations as it progresses with its mission in the biopharmaceutical industry.
Snapshot
Operations
Produtos e/ou serviços de Altamira Therapeutics
- RNA therapeutics platform focused on developing small interfering RNA (siRNA) treatments for various genetic and age-related hearing impairments.
- Nasal spray products designed for fast relief of symptoms related to allergies and common colds, emphasizing ease of use and effectiveness.
- Diagnostic tools for precise and early detection of hearing loss, utilizing cutting-edge technologies to improve outcomes and treatment pathways.
- Research partnerships with academic and medical institutions to explore novel treatments for ear, nose, and throat (ENT) disorders, fostering innovation and collaborative development.
equipe executiva do Altamira Therapeutics
- Dr. Thomas Meyer Ph.D.Founder, President, Chairman, CEO & MD
- Mr. Marcel Gremaud CPAChief Financial Officer
- Dr. Covadonga PanedaChief Operating Officer
- Dr. Samuel A. Wickline M.D.Chief Scientific Adviser